Table 2 | Meta-analysis of Ta1 CHB monotherapy..

Study Design	Study County	Subjects Enrolled	Clinical Outcome (at end of follow up)
Randomized, placebo-controlled double-blind[34]	United States Phase 2	20	Ta1 Placebo	83% 25%	p<0.04
Multicenter, randomized, placebo-controlled double-blind[111]	United States Phase 3	99	Ta1 Placebo	24% 12%	p<0.11
Multicenter, randomized, controlled[112]	Italy Phase 3	33	Ta1 IFN-alpha2b Historical control	41% 25% 7%	p=0.025
Multicenter, randomized, controlled open-label[113]	Taiwan Phase 3	158	Ta1 (6 mo Rx) Ta1 (12 mo Rx) Control	36% 27% 25%
Multicenter, randomized, controlled open-label[113]	Taiwan Phase 3	98¹	Ta1 (6 mo Rx) Ta1 (12 mo Rx) Control	41% 38% 9%	p<0.004 (6 mo vs. Control)
Meta-analysis [110]	United States, Taiwan, Italy	223	Ta1 (6 mo Rx) Control	36% 19%	p=0.04

Abbreviations: CHB = chronic hepatits B; IFN = interferon; Ta1 = thymosin alpha 1; vs. = versus
¹Data from the Chang Gung Memorial Hospital, the major site of the study

Table 2: Meta-analysis of Ta1 CHB monotherapy studies.

Goto home»